CA2370316A1 - Derives de la rhodanine et leur utilisation pour l'inhibition et la mise en images d'amyloides - Google Patents

Derives de la rhodanine et leur utilisation pour l'inhibition et la mise en images d'amyloides Download PDF

Info

Publication number
CA2370316A1
CA2370316A1 CA002370316A CA2370316A CA2370316A1 CA 2370316 A1 CA2370316 A1 CA 2370316A1 CA 002370316 A CA002370316 A CA 002370316A CA 2370316 A CA2370316 A CA 2370316A CA 2370316 A1 CA2370316 A1 CA 2370316A1
Authority
CA
Canada
Prior art keywords
thioxo
benzylidene
thiazolidin
oxo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370316A
Other languages
English (en)
Inventor
Corinne Elizabeth Augelli-Szafran
Shelly Ann Glase
Terri Stoeber Purchase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370316A1 publication Critical patent/CA2370316A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne une méthode permettant de traiter la maladie d'Alzheimer au moyen d'un composé représenté par la formule (I). L'invention concerne également une méthode permettant d'inhiber l'agrégation d'amyloïdes au moyen d'un composé représenté par la formule (I) ainsi qu'une méthode permettant de mettre en images des dépôts d'amyloïdes au moyen de dérivés substitués de la rhodanine.
CA002370316A 1999-06-10 2000-05-31 Derives de la rhodanine et leur utilisation pour l'inhibition et la mise en images d'amyloides Abandoned CA2370316A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13854599P 1999-06-10 1999-06-10
US60/138,545 1999-06-10
PCT/US2000/015072 WO2000076988A1 (fr) 1999-06-10 2000-05-31 Derives de la rhodanine et leur utilisation pour l'inhibition et la mise en images d'amyloides

Publications (1)

Publication Number Publication Date
CA2370316A1 true CA2370316A1 (fr) 2000-12-21

Family

ID=22482518

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370316A Abandoned CA2370316A1 (fr) 1999-06-10 2000-05-31 Derives de la rhodanine et leur utilisation pour l'inhibition et la mise en images d'amyloides

Country Status (8)

Country Link
EP (1) EP1192144A1 (fr)
JP (1) JP2003502321A (fr)
AU (1) AU5455400A (fr)
BR (1) BR0011440A (fr)
CA (1) CA2370316A1 (fr)
MX (1) MXPA01009863A (fr)
TR (1) TR200103561T2 (fr)
WO (1) WO2000076988A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
AU2003223805A1 (en) 2002-05-10 2003-11-11 Qlt Inc. Methods of using thiazolidine derivatives to treat cancer or inflammation
AU2003229459A1 (en) * 2002-05-17 2003-12-02 Qlt Inc. Methods of using thiazolidinedithione derivatives
JP2006510661A (ja) 2002-12-06 2006-03-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｐｉ３ｋの阻害剤としてのベンズオキサジン−３−オン類及びその誘導体
EP1622613A4 (fr) * 2003-05-14 2008-04-02 Cytokinetics Inc Composes, compositions et procedes
WO2005007123A2 (fr) * 2003-07-18 2005-01-27 Pintex Pharmaceuticals, Inc. Composes modulateurs de pin-1 et methodes d'utilisation associees
EP2121633A2 (fr) 2007-02-12 2009-11-25 Merck & Co., Inc. Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées
JP2012500222A (ja) * 2008-08-15 2012-01-05 バーンハム インスティテュート フォー メディカル リサーチ 金属酵素阻害剤の設計および開発のための組成物および方法
JP5733716B2 (ja) * 2009-12-25 2015-06-10 キヤノン株式会社 中枢神経系組織標識用組成物、中枢神経系組織の標識方法、及び中枢神経系組織標識用組成物を用いたスクリーニング方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D

Also Published As

Publication number Publication date
TR200103561T2 (tr) 2002-04-22
WO2000076988A1 (fr) 2000-12-21
EP1192144A1 (fr) 2002-04-03
MXPA01009863A (es) 2002-05-06
BR0011440A (pt) 2002-03-19
AU5455400A (en) 2001-01-02
JP2003502321A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
AU777747B2 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives
US6001331A (en) Method of imaging amyloid deposits
AU2004247013B2 (en) Compounds and uses thereof in modulating amyloid beta
PL215711B1 (pl) Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji
US6949575B2 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
CA2370316A1 (fr) Derives de la rhodanine et leur utilisation pour l'inhibition et la mise en images d'amyloides
EP1655287A1 (fr) Sonde pour maladies liees a l'accumulation d'amyloide, agent de coloration d'amyloide, remede et agent prophylactique de maladies liees a l'accumulation d'amyloide et sonde de diagnostic et agent de coloration en matiere de changement neurofibrillaire
CA2374616A1 (fr) Derives de rhodanine utilises dans un procede d'inhibition de l'agregation de proteines amyloides et de formation d'images de depots amyloides
US20040197268A1 (en) Method of imaging amyloid deposits using substituted rhodanine derivatives
US20040180943A1 (en) Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis
EP1193260B1 (fr) Analogues de phenoxazine pour le traitement d'amyloidose

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead